Expert Rev Clin Pharmacol. 2010;3(3):321-329. Despite a propensity to block hERG channel function, as determined by electrophysiology, for a limited number of compounds no cardiac arrhythmias have ...
New York, NY, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Polaris Market Research has published a recent study report titled "HERG Screening Market Share, Size, Trends, Industry Analysis Report, By Product Type ...
Non-specific binding of compound can affect the potency measurement from both conventional and automated patch-clamp assays. Because of this, pre-cautions need to be taken to ensure this is minimized ...
CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has received notification from ...
Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...
CiPA Initiative Aims to Better Detect Drug-Induced Cardiac Arrhythmias With cardiovascular side effects an ever-pressing concern in drug safety, interest is growing in ion channel assays and in silico ...
Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only ...
Novel Assays for Early Testing the Cardiac Liabilities of Compounds Novel test systems for assessing cardiac liabilities of compounds are continuously being developed and have reached fairly high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results